ClinicalTrials.gg
RecruitingNCT07683975Updated Nov 20, 2026

Infliximab for Immune Checkpoint Inhibitor Associated AKI

A Phase 4 interventional study of Infliximab and Prednisone in Acute Kidney Injury and Acute Interstitial Nephritis, sponsored by Massachusetts General Hospital. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Massachusetts General Hospital · Phase 4, Interventional, and Treatment

How we know

Updated Nov 20, 2026Now RecruitingStart date moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 370 studies in Acute Kidney Injury with a site in United States — 72 open to participants now, 88 under way, 9 of them phase 3. Acute Kidney Injury · United States.

Planned enrollment
143rd of 237
44 · median 67
Started
2026
with 28 others
Phase 4
23 of 370
6 open now
Primary completion
2029-01
later than 80 of 87 live
Registered
363rd of 370
by date

Among the 370 studies in Acute Kidney Injury with a site in United States, this one is the 143rd largest by planned enrollment of the 237 interventional ones that give a count, is one of 29 that started in 2026, is one of 23 in phase 4, reaches primary completion later than 80 of the 87 other live ones, and was the 363rd registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

72 of the 370 studies in Acute Kidney Injury with a site in United States are open now. Recruiting first, the newest first:

66 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 370 studies in Acute Kidney Injury with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, 1:1 randomized pilot study examining the efficacy and safety of infliximab 5mg/kg x 1 paired with 2 weeks of prednisone 1mg/kg per day for 2 weeks versus standard-of-care glucocorticoid therapy (prednisone 1mg/kg/day x 2 weeks followed by a 4 week taper) on the rate and speed of renal recovery from immune checkpoint inhibitor-associated AKI.

Read the detailed description

Data to guide treatment of immune-checkpoint inhibitor associated acute kidney injury (ICI-AKI) are limited, with current guidelines recommending 4-8 weeks of glucocorticoids (GCs). However, GCs have numerous side effects and can attenuate the anti-tumor response induced by ICI therapy, commonly leads to adverse events, and can delay anti-cancer therapy.

Infliximab is an FDA-approved monoclonal antibody that inhibits tumor necrosis factor-α and is used to treat a variety of autoimmune diseases, as well as steroid-refractory extrarenal immune-related adverse events. A strong biologic rationale exists for its use in patients with ICI-AKI, and case reports suggest some benefit in steroid-refractory ICI-AKI; however, there are no randomized clinical trial (RCT) data to guide the upfront use of infliximab in ICI-AKI.

This is a multi-center, 1:1 randomized pilot study examining the efficacy of infliximab in increasing the rate, speed, and durability of renal recovery when compared to standard of care prednisone which is current standard of care in patients receiving ICIs. The primary outcome is the rate of sustained renal recovery at 12 weeks. Key secondary outcomes include time-to-sustained renal recovery, time-to-ICI-AKI recurrence, and time-to-rechallenge with anti-cancer therapy. Additionally, we will characterize the safety profile of infliximab, as well a 6- vs. 2-week course of GCs, using the Glucocorticoid Toxicity Index.

03

Conditions studied

  • Acute Kidney Injury
  • Acute Interstitial Nephritis

Browse trials for

Keywords

  • acute kidney injury
  • acute interstitial nephritis
  • checkpoint nephritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years.
  • Acute kidney injury (AKI), defined as ≥1.5-fold increase in serum creatinine compared to baseline. Baseline is defined as the closest serum creatinine value prior to initiation (ICI).
  • Receipt of ICI in the 180 days preceding AKI onset.
  • AKI due to ICI-AIN, based on either a kidney or clinical adjudication by the treating team.
  • Ability of the patient to understand the study and willingness to sign the written form.

Exclusion criteria

Exclusion Criteria:

  • Any condition requiring high dose (GCs) (>10 mg/day prednisone equivalents) or other , such as infliximab, tocilizumab, mycophenolate mofetil, B cell depletion, or calcineurin inhibitors, within 14 days preceding screening
  • Evidence of any uncontrolled infection, including Tuberculosis (must have no evidence of active or latent TB determined by clinical history and negative interferon gamma release assay within the last 12 months or at screening); (based on AntiSAg and HBV DNA negative within the last 12 months or at screening. Patients with Isolated Anti-HBcore positivity must agree to antiviral prophylaxis with entecavir for 6 months after receiving infliximab); (must have no uncontrolled active infection evidenced by negative HCV antibody or HCV RNA within the last 12 months or at screening, and reflex testing must be performed for any patient with HCV antibody positivity); Patients with known must be on stable disease antiretroviral therapy ≥12 weeks with a negative viral load [\<50 copies/mL] at screening and ≥ 350 cells/uL) measured within the last 12 months.
  • History of to infliximab or murine proteins.
  • Moderate-severe ( class III/IV) heart failure or recent decompensation.
  • Any active or uncontrolled hepatitis (immune-mediated, viral, or drug-induced) defined as or ALT > 3 × or Total > 1.5 × ULN in the 14 days preceding screening. (Participants with Gilbert syndrome can be enrolled with elevated total bilirubin if their direct bilirubin is not > ULN)
  • History of demyelinating disease (e.g., multiple sclerosis) or optic neuritis.
  • Uncontrolled or recurrent serious infections (e.g., untreated abscess, active sepsis), requirement for oral or intravenous antibiotics, at screening.
  • Receipt of any in the 28 days preceding screening
  • Kidney showing primary lesion other than acute interstitial nephritis
  • \<12 weeks in the opinion of the investigator
  • Unable to tolerate study procedures, including IV insertion.
  • to GCs, including but not limited to, uncontrolled diabetes mellitus with inability to safely manage expected steroid-induced hyperglycemia, severe and active psychiatric disease requiring ongoing titration of psychiatric medications, active peptic ulcer disease, severe osteoporosis or high fracture risk, or other investigator-determined conditions where systemic GC or infliximab would pose unacceptable risk in the judgment of the investigator.
  • Vulnerable populations including children, prisoners, neonates and pregnant or breastfeeding patients
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    Infliximab

    Infliximab 5mg/kg x 1 and prednisone 1mg/kg per day (rounded to the nearest 10mg) x 2 weeks

    Drug: Infliximab · Drug: prednisone (oral)

  • Active comparator
    Prednisone per standard of care

    Prednisone 1mg/kg per day for 2 weeks (rounded to the nearest 10mg, maximum 100mg/day) followed by a 4-week taper, tapered by 0.2mg/kg/day per week.

    Drug: Prednisone

Interventions

  • Infliximab 5mg/kg x 1 and prednisone 1mg/kg per day (rounded to the nearest 10mg) x 2 weeks

  • Prednisone 1mg/kg per day for 2 weeks (rounded to the nearest 10mg, maximum 100mg/day) followed by a 4-week taper, tapered by 0.2mg/kg/day per week.

  • DrugPrednisoneStudies of PrednisonePrednisone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Prednisone 1mg/kg per day for two weeks (Rounded do the nearest 10mg and maximum dose of 100mg per day)

06

What researchers measure

Primary outcomes

  1. Acute kidney injury recovery at 12 weeks

    The proportion of patients achieving AKI recovery within 12 weeks is defined as return of serum creatinine to less than 1.5-fold baseline creatinine within the need for ongoing immunosuppression. (Active immunosuppression is defined as currently receiving \>10mg/day of prednisone equivalent or having received any non-glucocorticoid immunosuppressant within the last 2 weeks).

    Time frame: 12 weeks

Secondary outcomes

  1. Time to AKI recovery

    Time to AKI recovered is defined as the time in days to meeting criteria for AKI recovery as defined in the primary outcome.

    Time frame: 24 weeks

  2. Time to ICI-AKI recurrence

    Time to ICI-AKI recurrence is defined as \>= 1.5-fold rise in serum creatinine compared to the lowest serum creatinine achieved while receiving immunosuppression, occurring within 24 weeks following randomization and without a clear alternative more likely cause of AKI.

    Time frame: 24 weeks

  3. Change in serum creatinine

    Change from enrollment to follow-up serum creatinine

    Time frame: 24 weeks

  4. Tumor response

    Tumor response is determined using the RECIST 1.1 criteria, a widely accepted 4-category scale (complete response, partial response, stable disease, and disease progression).

    Time frame: 24 weeks

  5. Progression free survival

    Progression-free survival is defined as survival to 24 weeks with complete response, partial response, or stable disease

    Time frame: 24 weeks

  6. Overall survival

    Overall survival at 24 weeks

    Time frame: 24 weeks

  7. Adverse events leading to treatment discontinuation

    Summary of any adverse event that leads to treatment discontinuation

    Time frame: 6 weeks

  8. Adverse events of special interest

    Adverse events of infliximab inclusion infusion reaction, serious infection, headach, hepatotoxicity, serum sickness, autoimmune phenomenon, rash, new malignancy, congestive heart failure, neurotoxicity.

    Time frame: 30 days after completing study treatment

  9. Serious adverse events (SAE)

    An SAE is defined as an adverse event that meets any of the following criteria 1) results in death, 2) is life threatening, 3) requires or prolongs hospitalization, 4) results in persistent or significant disability/incapacity.

    Time frame: Up to 30 days after completing study treatment

  10. Glucocorticoid toxicity index

    The Glucocorticoid Toxicity Index (GTI) is a validated clinician-assessed instrument designed to prospectively quantify changes in glucocorticoid-associated morbidity over time. The GTI evaluates toxicity across multiple domains, including body mass index, glucose tolerance, blood pressure, lipid metabolism, myopathy, bone health, skin toxicity, neuropsychiatric effects, infection, ocular complications, and patient-reported symptoms. GTI will be assessed at baseline and at week 6. Higher GTI scores reflect greater glucocorticoid-associated toxicity, whereas improvements in score indicate a reduction in steroid-related adverse effects.

    Time frame: 6 weeks

07

Study locations

2 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The final data set will include data on demographics, laboratory values, clinical outcomes. We will share deidentified, cleaned Individual Participant Data (IPD). Appropriate measures, such as assigning a unique code to each participant and removing any identifiers, will be used in accordance with our local IRB and hospital guidelines.

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Jan 2029, 26 months after the start.

Of 46 non-industry phase 4 interventional studies under Acute Kidney Injury, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 57. This study's planned 26 months is close to that.

Counting every sponsor, half of 47 studies reached it within 30 months; a quarter within 14 and three quarters within 57.

Start moved twice since we started tracking on Sep 25, 2026: Jul 2026 → Nov 2026, last on Nov 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2026
First posted
Jul 6, 2026
StartActual
Nov 9, 2026was Jul 2026
Primary completionEst.
Jan 15, 2029
CompletionEst.
Jul 16, 2029
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 1, 2026
Sites
3 sites changed recruiting status (2 now recruiting, 1 now not yet recruiting)
Show 3 sites
  • Massachusetts General Hospital · Boston, United Statesno status→Recruiting
  • Brigham and Women's Hospital · Boston, United Statesno status→Recruiting
  • Dana Farber Cancer Institute · Boston, United Statesno status→Not yet recruiting
across 2 updates, Oct 1, 2026 – Oct 9, 2026
Start date
Jul 16, 2026→Nov 9, 2026 (actual)
moved 2 times, Oct 1, 2026 – Nov 20, 2026
Show all 3 updates
  1. Nov 20, 2026
    Start date Sep 15, 2026→Nov 9, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 9, 2026
    Brigham and Women's Hospital is now Recruiting
  3. Oct 1, 2026
    Not yet recruiting→Recruiting
    3 sites changed recruiting status (2 now not yet recruiting, 1 now recruiting)
    Show 3 sites
    • Massachusetts General Hospital · Boston, United Statesno status→Recruiting
    • Brigham and Women's Hospital · Boston, United Statesno status→Not yet recruiting
    • Dana Farber Cancer Institute · Boston, United Statesno status→Not yet recruiting
    Start date Jul 16, 2026→Sep 15, 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07683975
Responsible party
Meghan Sise (Associate Professor of Medicine, Massachusetts General Hospital) — Principal investigator
First posted
Jul 6, 2026
Start date
Nov 9, 2026
Primary completion
Jan 15, 2029 (estimated)
Completion
Jul 16, 2029 (estimated)
Last update
Nov 20, 2026

Study contacts

Meghan E Sise, MD
Contact
msise@mgb.org
6176433948
Meghan E Sise, MD
principal investigator · Massachusetts General Hospital
David Leaf, MD
principal investigator · Brigham and Women's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Infliximab

Start the discussion